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Modelling epilepsy in the mouse: challenges and solutions
Grant F. Marshall1,2, Alfredo Gonzalez-Sulser2,3 and Catherine M. Abbott1,2,*
ABSTRACT
In most mouse models of disease, the outward manifestation of a
disorder can be measured easily, can be assessed with a trivial test
such as hind limb clasping, or can even be observed simply by
comparing the gross morphological characteristics of mutant and
wild-type littermates. But what if we are trying to model a disorder with
a phenotype that appears only sporadically and briefly, like epileptic
seizures? The purpose of this Review is to highlight the challenges of
modelling epilepsy, in which the most obvious manifestation of the
disorder, seizures, occurs only intermittently, possibly very rarely and
often at times when the mice are not under direct observation. Over
time, researchers have developed a number of ways in which to
overcome these challenges, each with their own advantages and
disadvantages. In this Review, we describe the genetics of epilepsy
and the ways in which genetically altered mouse models have been
used. We also discuss the use of induced models in which seizures
are brought about by artificial stimulation to the brain of wild-type
animals, and conclude with the ways these different approaches
could be used to develop a wider range of anti-seizure medications
that could benefit larger patient populations.
KEY WORDS: Mouse, Epilepsy, Induced seizures, Genetic models
Introduction: what is epilepsy?
Epilepsy is one of the most common neurological conditions
worldwide, with an incidence of just under one in every hundred
people in the UK, and a peak in occurrence in very young and very
old people (Beghi and Giussani, 2018). It is a condition that results
from disruptions in network activity in the brain that manifests as
seizures. Although anti-seizure drugs [ASDs; also known as anti-
epileptic drugs (AEDs); see Glossary, Box 1] can be used to treat
patients, these have very variable efficacies and are palliative, as
there is no cure for epilepsy.
There are many different types of seizures with different origins
and frequencies. The three main categories of epilepsy, as defined
by the International League Against Epilepsy (ILAE), are based on
the origin of onset: seizures of generalised onset involve large
bilateral brain areas, focal onset seizures arise in a specific region on
one side of the brain, and the remaining category comprises seizures
of unknown onset. Sudden death in epilepsy (SUDEP; Box 1), when
an individual dies during or after a seizure and often while they are
sleeping, occurs in one in 1000 people with epilepsy who are
otherwise healthy each year.
The causes of epilepsy range from purely environmental, such as
traumatic brain injury, through multifactorial causes like brain
tumours, to purely genetic, like inherited single-gene disorders or de
novo heterozygous dominant mutations (Fig. 1). Epilepsy
frequently starts in later life and is usually associated with
underlying cardiovascular or neurodegenerative disease or with
physical insults such as head injury. The worldwide incidence in
over 65s is 240 in every 100,000 (Liu et al., 2016). However,
epilepsy is more common in childhood, with a particularly high
incidence in children under 2 years old (Wirrell et al., 2011).
Multiple monogenic epileptic encephalopathies (Box 1) have been
identified (for a detailed review, see McTague et al., 2016).
Importantly, in these cases, the epileptiform activity (Box 1) may, in
itself, be harmful to development and contributes to additional
cognitive and behavioural impairment.
Over a hundred single-gene causes of epilepsy have now been
identified, with no one gene underlying more than 1% of total cases
(reviewed in Helbig and Ellis, 2020). Initially, many of these were
inherited mutations in genes encoding ion channels. However, the
advent of exome and later whole-genome sequencing fostered the
discovery of many new epilepsy genes. Trio sequencing, which entails
sequencing of the exomes of both parents and the affected child, has
been a particularly successful approach for pinpointing mutations that
have arisen de novo.Without sequencing, these caseswould, of course,
not have been diagnosed as genetic as theymanifest sporadically rather
than running in families. Many of the newly discovered epilepsy genes
overlap with those found to be causative of autism, intellectual
disability and other neurodevelopmental disorders. These genes
encode not just ion channels, but proteins with roles ranging from
synaptic vesicle recycling (Dhindsa et al., 2015) and protein synthesis
(de Ligt et al., 2012; Lam et al., 2016) to basic metabolic functions like
glucose transport (Seidner et al., 1998). The underlying mechanisms
by which these newly identified mutations result in network disorders
often remain to be identified, depending on the function of the gene
and the ease with which mutations can be modelled. However, there
are some notable exceptions for which different mutations in a single
gene can lead to either a loss or gain of function, depending onwhether
the mutation is a nonsense or deletion, as opposed to a missense,
mutation. This distinction can be very important for therapy, as
discussed in more detail below.
How then, with this complex picture, can we best model epilepsy
in animals? Although we limit the discussions in this Review to
modelling epilepsy in mice, researchers also use other model
systems with their own advantages and disadvantages (Box 2).
Modelling epilepsy
In order to rationally design and test novel treatments for epilepsy,
researchers require whole-animal models that capture the relevant
human pathology. Animal models must have construct validity,
recapitulating the aetiology of the human disorder within a
homologous neurobiological context; they must have face
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validity, exhibiting the same or similar phenotypes as patients; and
they should ultimately have predictive validity, only responding to
treatments that are effective in patients with the modelled disorder
(Garner, 2014; Willner, 1984). Such models provide an indirect
window into human pathology, allowing us to identify novel drug
targets and to test the efficacy of therapies through preclinical trials.
Although there are fundamental differences between human and
mouse neurobiology at all levels of organisation (Hodge et al.,
2019), mice nevertheless represent strong candidate organisms for
modelling human neurogenetic disorders. Over 99% of mouse
genes have human homologues (Mouse Genome Sequencing
Consortium et al., 2002), and, within the brain, the spatial pattern
of gene expression is at least grossly conserved (Strand et al., 2007).
In terms of epilepsy, focal mouse models of temporal lobe epilepsy
(TLE; Box 1) mimic patients, in that ictal seizures emerge from the
hippocampal formation and then spread to the rest of the brain
(Riban et al., 2002). Similarly, cortical and thalamic structures are
responsible for generalised seizures in both humans and mouse
models (Cao et al., 2020).
Mouse models of epilepsy can be divided into genetic and
induced (Fig. 2). In genetic models, genetic lesions (or spontaneous
mutations) result in the emergence of spontaneous seizures. In
induced models, chemical, electrical or acoustic stimulation result in
either acute or chronic seizures, depending on the induction method
and protocol.
Genetic models
The development of programmable endonuclease-based genome
editing such as CRISPR/Cas9 has significantly streamlined the
generation of clinically relevant genetic mouse models (Gurumurthy
and Lloyd, 2019). Of course, if we want to model genetic epilepsies,
CRISPR/Cas9 enables us to generate models of specific missense
mutations, as well as complete knockouts, with relative ease. These
models are essential for understanding the underlying molecular
mechanisms and phenotypic consequences of specific mutations, and
can even be used as additional support where variants have been
discovered in patients but have not yet been definitively shown to be
causative. Genetic mouse models are also invaluable for studying the
behavioural outcomes of network disruptions in early development,
including the possibility of age-dependent reversibility, and are
necessary for testing any gene-specific therapies, whether precision
medicine-based therapeutics or gene therapy. There are, of course,
challenges posed by the presence or absence of modifier loci in
different inbred mouse strains, as discussed below. Similarly,
extrapolating results from single-gene models on inbred
backgrounds to human cases with highly variable genetic
backgrounds will not always be straightforward, but is likely to be
more successful in epileptic encephalopathies resulting from highly
penetrant mutations in single genes.
The genetic background of mouse models of epilepsy, whether
genetic or induced, can of course vary. This potential confounder
needs to be considered when comparing results from different
studies, even those using mice with apparently the same inbred
strain background. However, these phenotypic differences can also
be manipulated to identify genetic modifiers, and to modulate
seizure severity to suit the purpose of the experiment. For example,
the Scn2aQ54 model displays different stage of onset of seizures,
seizure frequency and survival, depending on whether the mutation
is on a C57BL/6J or SJL/J background. These differences were
exploited to identify Cacna1g as an epilepsy modifier gene
(Calhoun et al., 2016). Similarly, SJL/J mice with an Scn8aN1768D
mutation modelling an epileptic encephalopathy mutation seen in
patients have later seizure onset and increased survival in
comparison to mice with the same mutation on a C57BL/6J
background. Intercross experiments showed that a hypomorphic
mutation of Gabra2 in the C57BL6/J strain increased seizure
severity, suggesting that upregulation of the Gabra2 product could
be a future therapeutic strategy (Yu et al., 2020). Mouse models of
different mutations in Scn8a (Table 1) have also been used for
preclinical testing of drugs that have moved into clinical trials
(Meisler, 2019).
Importantly, genetic models can also be used to establish whether
mutations operate through a gain- or loss-of-function mechanism,
which can, in turn, provide crucial context for determining the
appropriate therapeutic approach. There are some notable cases
where, for example, different mutations in a single gene can lead to
either loss or gain of function, depending on whether the mutation is
a nonsense or deletion, as opposed to a missense, mutation (Davies
et al., 2020; Quraishi et al., 2020). This distinction can be very
important for therapy. In a recent striking example, researchers
found that epilepsy resulting from mutations in SCN2A usually had
an onset at less than 3 months of age, when the mutations were
missense, and that these cases responded well to sodium channel
blockers. By contrast, cases with disease onset at over 3 months
generally had truncating loss-of-function mutations and failed to
respond to sodium channel-blocking drugs, illustrating the
importance of understanding the underlying mode of action even
within a single gene (Wolff et al., 2017).
Although genetic models are clearly more useful for studying the
molecular mechanisms of specific epilepsies and for generating
targeted therapies, their value as preclinical models can be limited
Box 1. Glossary
Anti-seizure drug (ASD): medication to treat seizures in people with
epilepsy; these drugs are also known as anti-epileptic drugs (AEDs).
Electrographic seizures: seizures that are only identifiable by
monitoring with electroencephalography (EEG), with no outwardly
observable signs.
Epileptic encephalopathies: disorders in which epileptic activity in the
maturing brain contributes to severe progressive cognitive and
behavioural impairments beyond that predicted from the underlying
pathology.
Epileptiform: specific discharges in the brain, usually detected via EEG.
Interictal: the periods between seizures in a patient or animal model.
Lennox–Gastaut syndrome: a complex, rare and severe childhood-
onset epilepsy characterised by multiple and concurrent seizure types
and cognitive dysfunction.
Kindling: repeated induction of seizure activity leading to progressively
more severe seizures in terms of behaviour and duration.
Overt, convulsive or behavioural seizures: visually obvious seizures
that can be accurately and reliably detected without the need for EEG.
Examples include tonic-clonic seizures, convulsions and wild running.
Maximal electroshock seizure test: a highly effective test for detecting
novel ASDs in which an electrical pulse is given either through mouth or
scalp electrodes to induce generalised tonic-clonic seizures.
Myoclonic jerk: a brief and involuntary muscle spasm with irregular
muscle twitching.
Racine stages: a widely used observational system for categorising
seizure severity in animal models, originally proposed in the 1970s.
Sudden death in epilepsy (SUDEP): when an individual with epilepsy
dies suddenly and unexpectedly with or without evidence of a seizure
and where no other obvious cause of death can be found.
Temporal lobe epilepsy (TLE): is characterised by focal seizures that
originate in the temporal lobe of the brain. One-third of patients with TLE
have drug-resistant seizures.
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by their seizure phenotypes (or lack thereof ). Later, we will discuss
the limitations of genetic mouse epilepsy models in terms of seizure
manifestation, before discussing how these disadvantages may be
overcome.
Induced models
Induced models of epilepsy, in which otherwise healthy animals are
made to develop seizures either by exposure to a chemical
compound or to electrical stimulation (Fig. 2), have been utilised
for over 75 years. They have been instrumental in the identification
and development of treatments (Bialer et al., 2013, 2015, 2017,
2018; Fallah and Eubanks, 2020; Löscher, 2011, 2017). Electrical
shock or systemic or intracerebral injection of a convulsant
compound can trigger frequent and severe seizures in mice,
making the phenotypes of these models relatively easy to visually
quantify while also allowing for large throughput. From the
antiepileptic properties of trimethadione in 1945, which
eventually became a standard treatment for absence seizures,
which present outwardly as a sudden behavioural arrest (Everett and
Richards, 1945), to the maximal electroshock seizure test (Box 1;
Toman et al., 1946), which is still the most commonly used initial
readout for screens of new ASDs, induced mouse models have
played a crucial role in the discovery of many of the major epilepsy
treatments in use today (Löscher, 2017).
In so-called kindling (Box 1) protocols, researchers deliver
electrical (Leech and McIntyre, 1976) or chemical (Schmidt, 1987)
insults on multiple occasions. Once the animals are ‘kindled’,
seizures can be elicited on demand and novel treatments can be
tested. Similarly, quantifiable motor seizures can be generated
acutely by a systemic chemical injection of pilocarpine (Cavalheiro,
1995), kainate (Lévesque and Avoli, 2013) or pentylenetetrazole
(Karler et al., 1989). In chronic epilepsy models, neuronal damage
and reorganisation of connections lead to the emergence of
spontaneously occurring seizures, which better mimic clinical
epilepsy, as the seizures can occur at any time. For example, in the
systemic pilocarpine (Cavalheiro, 1995) and intrahippocampal
kainate (Riban et al., 2002) injection models, an initial insult
leads to a status epilepticus event that eventually subsides and is
followed by a refractory period lasting days to weeks. This coincides
with the emergence of hippocampal sclerosis and spontaneous
seizures. Furthermore, some ASDs are ineffective in these models,
mimicking TLE, which is often difficult to treat. Induced models are
therefore useful platforms for discovering new therapeutic strategies
that are able to block intractable seizures (Klein et al., 2015;
Lévesque and Avoli, 2013).
Challenges in finding new treatments
Despite progress in developing novel ASDs, a substantial
proportion of epileptic patients have drug-resistant epilepsy, for
which medication cannot manage the seizures. Under ILAE
definitions, the prevalence of drug resistance has been estimated
to range from 17% to 33% of all epilepsy cases (Kwan et al., 2010;
Ramos-Lizana et al., 2012; Téllez-Zenteno et al., 2014). Large
screening consortia, such as the Epilepsy Therapy Screening
Program, are now utilizing the above-discussed chronic and
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Fig. 1. The common causes of epilepsy, from purely genetic (blue) to purely environmental (yellow).
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seizures, to discover novel treatments for drug-resistant epilepsy
(Löscher, 2017). However, these models are more relevant to adult
TLE, for which disease mechanisms are likely to be very different
from those of genetic epilepsy syndromes such as epileptic
encephalopathies. As these syndromes often display drug-resistant
seizures in association with intellectual disability (Zhang et al.,
2017), researchers face the challenge of developing treatment for
drug-resistant epilepsies of vastly varying aetiologies.
Induced models can be relied upon to exhibit acute or chronic
seizures ‘on demand’ and therefore have high face validity, but their
Box 2. Genetically manipulable model systems for epilepsy beyond the mouse
iPSCs
Human induced pluripotent stem cells (iPSCs) were first generated in 2007
from fibroblasts and can now be efficiently generated from patients with
neurological disorders and healthy controls (Kogut et al., 2018; Takahashi
et al., 2007). Patient-derived iPSC lines are useful for modelling disorders
with complex genetic architecture, which would be impractical to model in
whole animals. Otherwise, control iPSC lines can also be edited using tools
such as CRISPR/Cas9 to recapitulate mutations seen in monogenic
disorders (Eggenschwiler et al., 2016).
Diverse neuronal and non-neuronal cell types can be differentiated from
iPSCs (Wiegand and Banerjee, 2019), enabling mechanistic studies and
drug screening in human tissue. The effect of candidate drugs on
spontaneous neural activity can be assessed at high throughput using
multi-electrode array setups (Tidball and Parent, 2016). Aside from
differences in the differentiation potential of iPSCs from different donors
(Kyttälä et al., 2016), human iPSC-derived neurons are slow to fully
differentiate (Nicholas et al., 2013) and slow to develop mature
electrophysiology (Prè et al., 2014). Moreover, human neuronal cultures
do not consistently develop synchronous network activity unless
co-cultured with human or murine astrocytes (Kuijlaars et al., 2016),
limiting their usefulness for modelling network disturbances in epilepsy.
However, recent advances in three-dimensional culture techniques and
differentiation methods have allowed the generation of cerebral organoids
from single iPSC lines. These organoids comprise diverse neuronal and
glial cell types, which show limited self-organisation and exhibit
spontaneous, synchronised neural activity (Izsak et al., 2019; Trujillo
et al., 2019; Zafeiriou et al., 2020), meaning that they could eventually
model both network-level and cell-autonomous defects in epilepsy.
Caenorhabditis elegans
The roundworm C. elegans has a relatively simple but exceptionally well-
characterised nervous system consisting of exactly 302 neurons (in the
adult hermaphrodite) with a highly stereotyped organisation (Chatterjee and
Sinha, 2007). C. elegans neurons are morphologically similar to
mammalian neurons and use conserved neurotransmitters, although
there are important physiological differences – C. elegans neurons have
ion channels but they do not have voltage-gated sodium channels
(Bargmann, 1998; Risley et al., 2016). Nevertheless, it has been
estimated that over 80% of protein-coding C. elegans genes have human
homologues (Lai et al., 2000). Seizure-like activity in C. elegans typically
includes convulsions or head bobbing. For example, worms with loss-of-
function mutations in GABAA receptors are susceptible to pentylenetetrazol
(PTZ)-induced head-bobbing convulsions (Williams et al., 2004; Wong
et al., 2018). Head bobbing can also be induced inC. elegans by increasing
their temperature above 26°C (Pandey et al., 2010).
C. elegans are cheap to maintain, reproduce rapidly, and can be treated
with drugs via food (Kaletta and Hengartner, 2006). Combined with easily
induced and assayed seizures, these features make them suitable for high-
throughput drug screening (Wong et al., 2018). Electrophysiological recording
is also possible in C. elegans (Goodman et al., 2012; Stawicki et al., 2013).
Drosophila
Around three-quarters of human disease genes have orthologues in
Drosophila (Bier, 2005; Pandey and Nichols, 2011). Researchers using
Drosophila as a disease model can exploit a wide variety of assays and
sophisticated genetic tools to understand gene function and disease
mechanisms (Ugur et al., 2016).
Drosophila have been used extensively as epilepsy models, with a
number of seizure-susceptible mutants available (Parker et al., 2011a). For
example, bang senseless is a gain-of-function mutation of the paralytic
gene, which encodes a voltage-gated-sodium channel subunit. parabss1 is
associated with a stereotyped sequence of spasms and paralysis
in response to various mechanical stimuli (Parker et al., 2011b).
Mutations in voltage-gated sodium channels also cause seizures and
epilepsy in humans (Feng et al., 2019), and several of these mutations
cause seizures in Drosophila when knocked into paralytic (Kroll et al.,
2015b). Seizures in parabss1 flies can be partially suppressed with anti-
seizure drugs (ASDs) or a ketogenic diet (Radlicz et al., 2019; Reynolds
et al., 2004), suggesting shared underlying pathophysiology with patients.
Furthermore, several Drosophila mutants have been identified that
suppress seizures in parabss1 flies (Kroll et al., 2015b; Saras and
Tanouye, 2016). The identification of seizure suppressor or enhancer
mutations in Drosophila can reveal novel therapeutic avenues.
Drosophila have lowmaintenance costs and a rapid life cycle, and can be
administered with drugs via food, making them suitable for high-throughput
drug screening. Moreover, electrophysiological recording and stimulation
are routinely performed at various stages of the life cycle (Kroll et al., 2015a;
Parker et al., 2011b; Ugur et al., 2016).
Zebrafish
Over the past decade, zebrafish have surged in popularity as models of
human neurological disorders (Fontana et al., 2018). It has been estimated
that 76% of human disease genes have a zebrafish orthologue (Howe et al.,
2013), and both larvae and adults are susceptible to seizures. Seizures can
be elicited using convulsants such as PTZ or kainic acid, or by genetic
manipulation, and typically involve hyperactive swimming followed by loss
of posture (Afrikanova et al., 2013; Baraban et al., 2013). Electrographic
seizures can be detected using EEG, which has been developed for use in
both larval (Lee et al., 2020) and adult (Cho et al., 2017) forms. Seizure
activity can also be directly visualised in the transparent larvae using
transgenic reporters (Burrows et al., 2020).
Zebrafish have high fecundity and are relatively cheap to maintain
(Avdesh et al., 2012). The larvae, arrayed in microtitre plates and video
recorded, can be used for high-throughput ASD screening (Baraban et al.,
2013; Griffin et al., 2016), with candidate drugs simply added to the water.
For example, a zebrafish model of Dravet syndrome (with mutations in the
SCN1A homologue scn1lab) shows face validity for behavioural and
electrographic seizures. Drug screening using this model identified
clemizole as a potential treatment for patients (Baraban et al., 2013).
Rats
As well as having similar gross brain anatomy, rats possess neural circuits
and patterns of network activity that are highly homologous to those in
humans (Heilbronner et al., 2016; Lu et al., 2012). Around three-quarters of
human disease genes have rat orthologues, and genes associated with
neurological disease are particularly well conserved (Huang et al., 2004).
Before the development of programmable endonucleases, the transgenic
tools available for rats were lagging behind the more sophisticated tools
available for mice. However, transgenesis and site-specific editing are now
equally feasible in rats (Ellenbroek and Youn, 2016; Guan et al., 2014;
Gurumurthy and Lloyd, 2019).
Rats have been extensively studied and are highly informative as acute
seizure models, and as kindling models, and have been instrumental for
ASD screening (Löscher, 2017). At present, the best-characterised genetic
rat epilepsy models are inbred strains carrying spontaneous mutations,
such the GAERS andWAG/Rij strains (Danober et al., 1998). However, rats
with clinically relevant mutations have also been studied (Ohmori et al.,
2020). Diverse EEG setups have been developed for both tethered (Medlej
et al., 2019) and wireless (McGuire et al., 2019) EEG in rats, and ex vivo
brain slice preparations can be used to study seizure susceptibility (Accardi
et al., 2018) and epileptogenesis (Dyhrfjeld-Johnsen et al., 2010), and to
screen ASDs (Hill et al., 2010).
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relevance to human epilepsies remains contentious. One may contend
that, even though they trigger repeated seizures, chemical or electrical
induction are not genuine causes of human epilepsy and will therefore
fail to recreate the precise cellular andmolecular pathology of any bona
fide aetiology, limiting our ability to extrapolate findings to humans
(Bertram, 2007; Löscher, 2011). Conversely, genetic models can
precisely recapitulate the genetic mutations that cause epilepsy in
patients and thus have high construct validity. Although it is clear that
researchers need both induced and genetic models for maximal drug
development efficiency, genetic models are likely to become
increasingly important for developing properly targeted therapies.
Indeed, the concept of precision medicine has had some notable
successes in epilepsy, albeit mainly in the field of metabolic epilepsies.
The most striking example of this is seen in GLUT1 deficiency, where
mutations in the SLC2A1 gene, which encodes a glucose transporter
in the blood brain barrier (GLUT1), lead to low glucose in the
cerebrospinal fluid, resulting in seizures and developmental delay
(Seidner et al., 1998). Treating affected children with a ketogenic diet
so that their neurons use ketone bodies as an energy source results in
good seizure control (Fujii et al., 2016). This progress in precision
Genetic models
EEG recordings
Clinically relevant mutations identified









Filtering Digitisation EEG display and analysis
Seizures inducedNovel model for
characterisation
A T G C G A C T




Fig. 2. Generation and characterisation of rodent epilepsymodels.Genetic models are generated by knockout or knock-in mutagenesis. In induced models,
seizures are typically elicited by chemical, electrical or acoustic stimulation of the brain. In both model types, the seizures are the key phenotypic readout and can
be accurately and reliably detected using electroencephalography (EEG). Rodent EEG begins with the installation of electrodes or electrode arrays on the skull
surface in the case of conventional EEG or beneath the skull for intracranial EEG or electrocorticography. Intracranial electrodes may be positioned at the brain
surface or at a higher depth. Synchronised neuronal activity near the electrodes generates the EEG signal that undergoes various stages of amplification, filtering
and digitisation before finally being displayed (Moyer et al., 2017). EEG signals may be transmitted from the animal to the computer via a cable (tethered
recording) or wirelessly (wireless telemetry). ES cells, embryonic stem cells.
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Table 1. Selected validated models of genetic epilepsies
Mouse
gene
symbol Mutation class Name/function of gene product Phenotype/key findings References
Arfgef1 Frameshift (null) ADP ribosylation factor guanine
nucleotide exchange factor 1;
intracellular vesicle trafficking.
No spontaneous seizures, increased
susceptibility to induced seizures.
(Teoh et al., 2020)
Arx Triplet repeat expansion Aristaless-related homeobox;
plays a role in developmental
patterning.
Neonatal seizures, EEG abnormalities;
treatment with E2 hormone reduces seizure
burden if administered during first week of
life.
(Siehr et al., 2020)
Cdkl5 Null and missense Cyclin-dependent kinase-like-5;
protein kinase.
Spontaneous seizures seen only in aged
mice.
(Mulcahey et al., 2020)
Chrna4 Null and missense Cholinergic receptor nicotinic
alpha 4 subunit; ion channel.
Frequent spontaneous seizures in
heterozygous mice.
(Klaassen et al., 2006)
Cntnap2 Null Contactin-associated protein-
like 2; role in cell adhesion.
Spontaneous seizures after 6 months,
induced by handling.
(Peñagarikano et al., 2011)
Dnm1 Null and ‘fitful’missense Dynamin 1; role in clathrin-
mediated endocytosis.
Homozygous fitful mice have early lethal
seizures, older heterozygotes have
spontaneous mild seizures. Null mutation is
lethal in homozygotes but no seizures seen
in heterozygotes. Comparison between
mutations demonstrates that the missense
mutation has a gain-of-function/dominant-
negative mechanism of action.
(Asinof et al., 2016)
Eef1a2 Null and missense Translation elongation factor
1A2; crucial for neuronal
protein synthesis.
Spontaneous audiogenic seizures (AGSs)
seen in null homozygotes, no seizures
observed in missense homozygotes or
heterozygotes. Phenotyping revealed gain
of function of missense mutants.
(Davies et al., 2017, 2020)
Epm2a Null Laforin; regulation of glycogen
metabolism.
Spontaneous seizures by 9 months in
knockout, which is a model for Lafora
syndrome.
(Ganesh et al., 2002)
Fmr1 Null and triplet repeat
expansion
Fragile X mental retardation 1;
regulator of translation.
Increased susceptibility to AGSs but no
spontaneous behavioural seizures
observed; AGS susceptibility depends on
age of animal, differs according to sex.
(Musumeci et al., 2000)
Gabra1 Truncation Gamma-aminobutyric acid type
A (GABAA) receptor alpha 1
subunit; neurotransmitter
receptor.
Homozygous null animals develop severe
seizure phenotype by 19 days;
homozygous phenotype is lethal soon after
birth. Heterozygotes show increased levels
of sudden death by 4 weeks.
(Vicini et al., 2001)
Gabrg2 Null and missense GABAA receptor gamma 2
subunit; neurotransmitter
receptor.
Both null and missense heterozygotes exhibit
spontaneous seizures.
(Kang et al., 2015; Warner et al.,
2016)
Gabra3 Missense GABAA receptor alpha 3 subunit;
neurotransmitter receptor.
Novel model of Lennox–Gastaut syndrome
(Box 1). Fatal seizures in homozygotes after
a few weeks; heterozygotes display
spontaneous atypical absence seizures, as
well as less frequent tonic, myoclonic,
atonic and generalised tonic–clonic
seizures. Absence seizures blocked by
ethosuximide, clobamazan and a
cannabinoid.
(Qu et al., 2020)
Gria2 Null and editing
defective
Glutamate ionotropic receptor
AMPA type subunit; glutamate
receptor.
Spontaneous seizures in both heterozygotes
and homozygotes.
(Brusa et al., 1995)
Grin2a Missense Glutamate ionotropic receptor N-
methyl-D-aspartate (NMDA)
type subunit 2A; ion channel.
Fatal seizures in homozygotes by a fewweeks
of age, heterozygous animals show
increased susceptibility to induced
seizures. Treatment with NMDA receptor
agonists delays, but does not prevent,
seizure onset in homozygous pups.
(Amador et al., 2020)
Iqsec2 Null IQ motif and Sec7 domain 2;
guanine nucleotide exchange
factor.
Fatal seizures in adult heterozygotes but
paradoxical resistance to induced seizures.
(Sah et al., 2020)
Kcnq2 Null, missense Potassium voltage-gated
channel subfamily Q member
2; ion channel.
Early-onset generalised seizures in null
homozygotes. No spontaneous seizures in
heterozygous missense mice, but these
animals show increased susceptibility to
induced seizures and death during and after
kindling.
(Singh et al., 2008; Otto et al., 2009)
Continued
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medicine suggests that the availability of genetically altered mouse
lines recapitulating specific clinical mutations could lead to the
development of properly targeted, individualised therapies for groups
of patients (Helbig and Ellis, 2020).
Problems of two sorts with genetic mouse models
In the field of epilepsy research, the major challenge no longer lies
in the generation of genetic models but in assessing their face
validity: do these mutant mice have seizures and, if so, how frequent
and severe are they?
As in humans, seizures in mice are typically detected and
classified using a combination of electroencephalography (EEG)
and behavioural signs, such as convulsions or myoclonic jerks
(Box 1). Although all seizures involve epileptiform brain activity,
not all seizures have obvious behavioural manifestations. For




symbol Mutation class Name/function of gene product Phenotype/key findings References
Kcnq3 Null Potassium voltage-gated
channel subfamily Q member
3; ion channel.
Early-onset generalised seizures in null mice. (Singh et al., 2008)
Lgi1 Null Leucine-rich glioma-inactivated
1; secreted neuronal protein.
Early-onset spontaneous seizures and
seizure-related death.
(Chabrol et al., 2010)
Mecp2 Null, missense and
truncations
Methyl CpG binding protein 2;
transcriptional repressor.
Progressive age-dependent spontaneous
epileptiform discharge activity; handling-
dependent behavioural seizures. Model
used to test critical periods for gene
reactivation.
(Chao et al., 2010; D’Cruz et al.,
2010; Guy et al., 2007)
Nlgn2 Null Neuroligin-2; cell adhesion. Spontaneous absence seizures in
homozygotes; blocking absence seizures
pharmacologically and through gene
therapy rescues motor and social
impairments.
(Cao et al., 2020)
Pcdh19 Null (complex disorder
of cellular mosaicism
affecting females)
Protocadherin 19; cell adhesion. No spontaneous seizures but animals show
spike wave discharges on EEG.
(Gecz and Thomas, 2020)
Scn1a Null and missense,
many different alleles
Sodium voltage-gated channel,
alpha subunit 1; ion channel.
Variety of seizure types plus SUDEP – these
models have been reviewed extensively
and largely phenocopy the human disorder
well.
(Ogiwara et al., 2007; Yu et al., 2006;
Martin et al., 2010; Fallah and
Eubanks, 2020; Gu and Dalton,
2017; Gonzalez-Sulser, 2020)
Scn1b Null Sodium voltage-gated channel,
beta subunit 1; ion channel.
Homozygotes show early-onset spontaneous
seizures and sudden death at 3 weeks;
heterozygous nulls have no spontaneous
seizures or increase in susceptibility to
induced seizures. If knockout is delayed
until adulthood, the animals still develop
spontaneous seizures and mortality within
20 days.
(Chen et al., 2004; Patino et al.,
2009; O’Malley et al., 2019)
Scn2a Null and missense Sodium voltage-gated channel,
alpha subunit 2; ion channel.
Absence seizures in heterozygous nulls. (Miyamoto et al., 2019)
Scn8a Missense Sodium voltage-gated channel,
alpha subunit 8; ion channel.
Spontaneous seizures develop by 2-8 weeks
depending on mutation, followed by death
within hours/weeks. Drugs have been
tested on mice to good effect.
(Gu and Dalton, 2017; Papale et al.,




SH3 and multiple ankyrin repeat
domains 3; post-synaptic
density scaffold protein.
Spontaneous seizures; 50% die by 12 weeks. (Han et al., 2013; Jin et al., 2018)
Stxbp1 Null Syntaxin binding protein 1;
synaptic vesicle function.
Absence seizures and spike wave discharges
in heterozygous nulls.
(Kovacevic et al., 2018; Miyamoto
et al., 2019)
Syngap1 Null Synaptic Ras GTPase activating
protein 1; regulates receptor
trafficking at the post-synaptic
density.
No spontaneous seizures but increased
interictal activity and increased
susceptibility to induced seizures. Animals
have been used to test critical periods for
gene reactivation.
(Creson et al., 2019; Ozkan et al.,
2014)
Tsc1/2 Null Tuberous sclerosis complex 1/2;
regulation of growth signalling.
Spontaneous tonic-clonic seizures found in
null het mice at P16. GluN2C/D antagonists
block seizures in Tsc1+/−mice in vivo and in
vitro.
(Zeng et al., 2011; Lozovaya et al.,
2014)
Ube3a Null; multiple alleles
available
Ubiquitin conjugating enzyme
3a; targeting proteins for
degradation.
No spontaneous seizures but increased
susceptibility to AGSs or induced seizures.
EEG abnormalities. Used to test gene
reactivation critical periods.
(Jiang et al., 1998; Rotaru et al.,
2020; Judson et al., 2016)
Note that some models comprise extensive allelic series and have been reviewed in depth recently (see Fallah and Eubanks, 2020; Gu and Dalton, 2017). We have
omitted models of disorders that primarily manifest as cortical malformations or ataxia and those that rely on conditional knockouts to disrupt network activity. EEG,
electroencephalography; SUDEP, sudden death in epilepsy.
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classical Racine stages (Box 1) have been developed to measure
seizure severity (Chung et al., 2009; Racine, 1972; Singh et al.,
2008). The duration of seizures can also be used as a measure of
severity (Wu et al., 2020).
Frequent, overt (Box 1), but non-fatal, seizures represent ideal
face-valid epileptic phenotypes: not only are they unambiguous, but
they represent a direct and easily assayed readout for whether
experimental treatment attempts have been effective in reducing
seizure frequency or severity. Unfortunately, however, many
genetic mouse models of epilepsy have seizure phenotypes that
are not so conveniently assayed. In general, there are problems of
two sorts: seizures that are difficult to measure and seizures that are
overly severe and fatal.
Problems of the first sort: seizures that are difficult to measure
Researchers must reliably detect and score seizures in order to
obtain an accurate baseline against which to compare animals
receiving experimental treatments. However, many models have
relatively rare seizures, making accurate quantification difficult
without continuous, long-term EEG-video recording. For example,
there are many genetic mouse models in which spontaneous
seizures occur only once per week or less (Kash et al., 1997; Malas
et al., 2003; McColl et al., 2006; Singh et al., 2008). In some
models, seizures are spread unevenly over time. In the widely used
A/J (The Jackson Laboratory) mouse strain, seizures occurred
mostly during sleep (Strohl et al., 2007), in common with many
epilepsy patients (Chokroverty and Nobili, 2017). Other models
only have spontaneous seizures within certain age ranges. For
example, Tsc1+/− mice develop frequent, spontaneous seizures at
post-natal day (P)9 that resolve by 3 weeks of age (Gataullina et al.,
2016; Lozovaya et al., 2014). By contrast, Pum2-deficient mice do
not develop spontaneous seizures until 5 months of age (Follwaczny
et al., 2017). The timeline for spontaneous seizure emergence can
also differ substantially between patients and models. For example,
mouse models of CDKL5 deficiency disorder have failed to exhibit
the early-onset spontaneous seizures that occur in human patients
(Amendola et al., 2014; Fehr et al., 2016; Okuda et al., 2017).
Instead, spontaneous seizures in these models emerge well into
adulthood at around 10 months of age (Mulcahey et al., 2020).
Aside from seizure rarity, many models exhibit non-convulsive
electrographic seizures (Box 1) that may be difficult to detect or
score. This is especially true for models with absence seizures
(Chung et al., 2009; Jarre et al., 2017; Tan et al., 2007). The
behavioural arrests typical of these seizures are often frequent but
are inherently difficult to quantify without EEG recordings (Chung
et al., 2009; Jarre et al., 2017). Other subtle seizures such as brief
myoclonic jerks may also prove difficult to monitor. In one study of
Fosb-null mice, sudden behavioural arrests and myoclonic jerks
were simply not recorded owing to the inherent difficulty in
quantifying them (Yutsudo et al., 2013).
Problems of the second sort: severe, fatal seizures
In contrast to models with rare or subtle seizures, many genetic
epilepsy models suffer from severe but fatal seizures. Typically,
such models show a sudden spike in mortality concomitant with the
onset of spontaneous seizures in early life, resulting in a
dramatically reduced life expectancy (Bunton-Stasyshyn et al.,
2019; Chung et al., 2009; Kerjan et al., 2009; Meikle et al., 2007;
Zhang et al., 2016). For example, Dcx; Dclk2-null mice show
increased mortality after the onset of spontaneous seizures around
P16, with over 90% of mice dying by 5 months of age (Kerjan et al.,
2009). This limits the translational value of such genetic models as
longitudinal studies are not possible. It is also difficult to ethically
justify the use of sudden death as an outcome measure for
experimental treatments. Furthermore, as many of these models die
after a limited number of seizures, some after a single seizure
(Kerjan et al., 2009; Meikle et al., 2007), they are arguably less
relevant for modelling epilepsy than as models for SUDEP (Moore
et al., 2014; Wagnon et al., 2015).
Can we get around the seizure quantification challenges
in genetic models?
For researchers who have developed genetic models but have failed
to detect spontaneous seizures, the question is whether the model
has problems of the first sort – seizures that are difficult to measure –
or whether the model simply has no face-valid phenotype.
Answering this question is of key translational importance. Face
validity does not only mean that relevant readouts are available for
preclinical studies; it ultimately reflects the construct validity of the
model, which extends beyond whether an orthologous gene exists.
For example, a study has recently shown that mice recapitulating the
D252H missense mutation in neuronal translation-elongation factor
eEF1A2, which is associated with neurodevelopmental disorders
and late childhood epilepsy, do not show face validity for
spontaneous seizures or neurodevelopmental deficits, despite the
fact that human and murine eEF1A2 are almost identical (Davies
et al., 2020). These mice were not studied beyond 1 year of age, and
it is possible that spontaneous seizures may have developed later, in
line with the late onset in children. Nevertheless, their apparent lack
of face validity demonstrates how recapitulating clinically relevant
mutations in orthologous genes is not always sufficient to generate a
face-valid disease model. Only if the biochemical milieu of the gene
products is highly conserved between mice and humans, and only if
pathological changes occur within a homologous developmental
and neurobiological context, will human epileptogenic mutations
also be epileptogenic in mice (Belzung and Lemoine, 2011). The
ability to conclusively test face validity in genetic models is
therefore vital if we wish to exclude models that are unlikely to
provide a window onto human pathology (Garner, 2014).
Where genetic models fail to exhibit detectable spontaneous
seizures, one recourse is to induce seizures using chemoconvulsants
or auditory stimuli. By varying the auditory stimulus or
chemoconvulsant dose, researchers can assess whether genetic
mutants have increased seizure susceptibility compared with
controls (De Sarro et al., 2004; Musumeci et al., 2000; Okuda
et al., 2017; Pacey et al., 2009). This approach seems to marry the
precision of genetic models with the utility of induced models in
terms of seizure measurement. However, the fact remains that these
models do not have seizures without the application of
proconvulsant stimuli.
As discussed above, it is clear that the clinical community
requires new ASDs with novel targets and mechanisms of action to
address drug resistance in epilepsy. There is also a pressing need to
develop disease-modifying anti-epileptogenic therapies that can
reverse epileptogenesis rather than only providing seizure control
(Baulac et al., 2015; Bialer et al., 2018; Pitkänen et al., 2013). If
researchers can find ways to validate clinically relevant genetic
models of epilepsy, we will have succeeded in capturing the
pathophysiology associated with diverse epilepsy aetiologies. These
models could then be used for the discovery of novel anti-seizure or
anti-epileptogenic drugs.
To improve assessments of face validity in genetic models of
epilepsy, researchers have continued to develop video-EEG seizure
monitoring and are generating alternatives to EEG-based seizure
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detection. Continuous video-EEG monitoring is the gold-standard
approach for characterising both genetic and induced rodent
epilepsy models (Fig. 2), as it facilitates accurate and reliable
seizure detection (Gu and Dalton, 2017). Over the past decade, there
have been advances in the development of both the hardware and
software used to capture and analyse rodent EEGs. Besides the open
sharing of system designs and acquisition software, multi-channel
electrophysiology amplifiers have decreased in price by orders of
magnitude, enabling more research laboratories to rapidly and
inexpensively implement recording systems (Hermiz et al., 2016;
Siegle et al., 2017; Wasilczuk et al., 2016). Signals can be digitised
directly on the mouse through advance head-stage amplifiers, thus
negating artefacts caused by cable movement.Meanwhile, advances
in microelectrode fabrication techniques allow high channel counts
in a relatively small surface area, enabling the acquisition of EEGs
with higher spatial resolution and brain coverage (Obien et al., 2014;
Wasilczuk et al., 2016). Furthermore, multiple wireless recording
systems are now available that allow long-term recordings without
tethering mice, providing an opportunity for improved animal
welfare (Chang et al., 2011; Jiang et al., 2017; Lidster et al., 2016).
As many epilepsy models have only rare seizures, researchers
need to record and monitor animals for a period of weeks to months
to establish an accurate seizure baseline (Gu and Dalton, 2017). To
streamline the detection and quantification of EEG abnormalities
over these timescales, numerous freely available open-source
algorithms can automatically detect interictal (Box 1) spikes and/
or seizures from rodent EEGs (Anjum et al., 2018; Bergstrom et al.,
2013; Brown et al., 2018; Buteneers et al., 2011; Casillas-Espinosa
et al., 2019; Colasante et al., 2020; Jang and Cho, 2019; Pfammatter
et al., 2019; Tieng et al., 2016, 2017; Wykes et al., 2012), either
offline or in real time. EEG traces typically contain artefacts caused
by electromagnetic or biophysical interference (Kadam et al., 2017;
Pfammatter et al., 2019), but many algorithms can automatically or
semi-automatically filter these out (Anjum et al., 2018; Bergstrom
et al., 2013; Buteneers et al., 2011; Casillas-Espinosa et al., 2019;
Tieng et al., 2016). As a result, many of these systems report
sensitivities and specificities approaching 100% for the detection of
epileptiform EEG abnormalities (Anjum et al., 2018; Bergstrom
et al., 2013; Buteneers et al., 2011; Casillas-Espinosa et al., 2019;
Jang and Cho, 2019; Pfammatter et al., 2019; Tieng et al., 2016).
Automating EEG-based detection of seizures will allow
researchers to overcome many of the challenges associated with
validating genetic epilepsy models with problems of the first sort,
including rare seizures or seizures that predominantly occur during
certain stages of the sleep-wake or life cycles. Indeed, algorithms
have successfully detected and tracked seizures occurring as rarely
as 0.3 times per week (Anjum et al., 2018). Moreover, automated
seizure classification could remove the subjectivity and human error
inherent to manual EEG interpretation that often result in
considerable variability (Abend et al., 2011; Duez et al., 2018;
Halford et al., 2015).
Despite these technical advances, there remain issues relating to
the use of EEG in rodents, especially long-term continuous EEG.
The implantation of intracranial electrodes or installation of
electrode arrays is an invasive and time-consuming surgical
procedure, which itself could cause damage leading to epileptic
activity (Burman and Parrish, 2018). Moreover, to prevent animal
injury and damage to recording equipment, animals are often
housed singly, both post-operatively and over the duration of
continuous EEG recordings, which can last for months. Mice and
rats are social animals and it is now well established that single
housing causes stress (Ieraci et al., 2016; Lukkes et al., 2009;
Manouze et al., 2019; Weintraub et al., 2010). Social isolation of
young mice results not only in behavioural abnormalities but also
increased seizure susceptibility in adulthood (Amiri et al., 2017).
There is also evidence that social isolation can affect seizure
phenotypes in adult male mice (Amiri et al., 2014; Matsumoto et al.,
2003). Meanwhile, a recent study in rats showed that socially
isolated animals had a 16-fold increase in spontaneous seizure
frequency following treatment with the cholinergic agonist
pilocarpine (Manouze et al., 2019).
Researchers need to develop accurate and reliable methods of
seizure detection that are minimally invasive and that can be
employed in group-housed rodents over extended time periods. In
recent years, the most promising developments towards this goal
have come from radio-frequency identification (RFID)-assisted
in-cage monitoring systems (Fig. 3).
In-cage monitoring systems were developed to meet the need for
continuous assessment of unforced behaviours in rodents. At
present, the majority of these systems require single housing.
However, a growing number of systems are capable of continuously
monitoring individual animals within groups using subcutaneous
RFID tags (Bains et al., 2016; Krackow et al., 2010; Peleh et al.,
2019). Although there are currently no in-cage monitoring systems
with validated seizure-detection capabilities, both continuous video
capture and animal movement tracking present opportunities for
non-invasive detection of overt seizures. In a recent study, Jankovic
et al. (2019) employed a video-based movement tracking system
called EthoVisionXT to continuously monitor animals following
repeated injections of the convulsing agent pentylenetetrazole
(Jankovic et al., 2019). The authors found that convulsive seizures
(Box 1) were associated with brief spikes in whole-animal mobility
and used these spikes to highlight sections of the recording to
further screen for seizures. Although the study did not report the
sensitivity and specificity of this approach, it established the
potential for mobility-based seizure screening in rodents exhibiting
the most overt seizures.
Aside from gross motion tracking, home-cage video monitoring
could eventually enable the detection of behavioural seizures
(Box 1) based on finer visual features. Machine-learning approaches
have been used to generate video-based classifiers that can
recognise and score a range of rodent behaviours in real time or
offline. The repertoire of such detectable behaviours is constantly
expanding and currently includes locomotion and climbing (Bains
et al., 2018), eating and rearing (Aniszewska et al., 2014), and more
subtle behaviours such as scratching (Park et al., 2019) and head
bobbing (Baker, 2011). Video-based classifiers for seizures have
not yet been developed, but many of the behaviours for which
classifiers currently exist – such as rearing, scratching and head
bobbing – are seen in rodent seizures (Kandratavicius et al., 2014)
and could form the basis for future classifiers. The generation of
video-based classifiers for overt seizures is likely to be labour
intensive, requiring manual classification of many instances of a
given seizure type (Sturman et al., 2020). However, once classifiers
are developed for a given type of seizure, they could be used to
characterise other models with similar seizure presentations.
Movement or video-based seizure detection would necessarily be
limited to seizures with overt behavioural involvement. As
discussed above, many rodent epilepsy models exhibit only
electrographic or absence seizures, which will always require
EEG for detection. Nevertheless, robust, non-invasive seizure
monitoring would represent an important refinement for the subset
of epilepsy models that exhibit overt seizures and that have already
been characterised electrographically.
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Even without seizure-detection capabilities, in-cage monitoring
is a relevant approach in preclinical epilepsy research. There is a
growing appreciation of epilepsy as a spectrum disorder including
not only spontaneous and recurrent seizures, but also cognitive,
social and behavioural deficits (Fisher et al., 2014; Greenberg and
Subaran, 2011; Holmes and Noebels, 2016; Sirven, 2015). These
deficits can be the sequelae of chronic seizures or epileptiform
activity, i.e. epileptic encephalopathy, but can also arise in parallel
with seizures as a result of genetic mutations. In-cage monitoring of
group-housed animals offers the opportunity to study levels of
activity and social interaction in an ethologically relevant context,
unlocking new behavioural domains in which face-valid
phenotypes might be present. This could enhance the translational
value of genetic epilepsy models by allowing direct assessment of
any reversal of social and behavioural deficits during preclinical
trials.
Conclusions
To make progress in finding new treatments for epilepsy, as with all
disorders, researchers will need to develop a range of different
model systems (Box 2) and use them in a rational, integrated way.
Initial drug screening can be carried out cheaply and efficiently in
model systems like zebrafish larvae, where specific genetic
alterations can be induced using CRISPR gene editing.
Convulsive swimming movements can be captured with video
monitoring and scored, with larvae arrayed in microtitre plates in
which different wells can be exposed to different drugs. This system
allows for initial high-throughput, relatively cheap screening that
can then be followed up with electrophysiological confirmation
(Griffin et al., 2016). Candidate drugs from such screens can then be
directly tested in appropriate mammalian models; ultimately,
rational drug design may allow direct mammalian testing
approaches.
Novel therapies for epilepsies, even for those not caused by
mutations in a single gene, may also emerge from the fields of gene
therapy/gene targeting. Conventional gene therapy, in which loss of
function of a specific gene is corrected by delivery of a viral vector
encoding the missing product, is already being tested in monogenic
epilepsy models (e.g. Niibori et al., 2020). Further developments
include the use of antisense oligonucleotides to upregulate
expression of the sodium channel Nav1.1, leading to a reduction
in seizure frequency and severity in a mouse model of Dravet
syndrome (Han et al., 2020).
Additional novel approaches that target the underlying
mechanisms rather than specific genes could allow wider
populations to be treated. Recent striking examples include the
testing of autoregulatory gene therapy, in which neurons are
inhibited in response to rises in extracellular glutamate (Lieb et al.,
Video dataIR lightingPositional data
Discriminate individual animals Automated behaviour recognition
Fig. 3. RFID-assisted in-cagemonitoring system. Standard rodent cages are placed within the in-cagemonitoring system, where cameras positioned above or
at the side of the cage allow continuous video monitoring. Infra-red (IR) cameras and illumination are preferred as they allow animals to be visualised during the
dark phase of their 24-h light/dark cycle (Bains et al., 2016; Gu and Dalton, 2017). The majority of in-cage monitoring systems can only monitor single animals
(Bains et al., 2018). Increasingly, subcutaneous radio-frequency identification (RFID) chips (depicted as green tags in the figure) are being used to discriminate
individual animals within groups (Bains et al., 2016; Krackow et al., 2010; Peleh et al., 2019). The position of several RFID-tagged animals can be continuously
tracked as they move over an RFID antenna array (red dots) beneath the home cage and/or near areas such as water bottles or food hoppers.
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2018) and the use of CRISPRa (which modulates promoters) to
upregulate expression of the potassium channel gene Kcna1 in
excitatory neurons, dampening neuronal excitability and reducing
seizure frequency in a mouse model (Colasante et al., 2020).
Thus, the use of multi-pronged strategies may also allow us
eventually to circle back from the initial blunt approach of finding
drugs that treated seizures with no regard to underlying cause, to
finding that therapies initially designed for monogenic epilepsies
may, in fact, benefit much broader patient groups on the basis of
their underlying genetic susceptibilities. Heritability estimates
based on twin studies support a strong genetic component in
epilepsy overall (Kjeldsen et al., 2001; Miller et al., 1998), and up to
80% of epilepsy cases are attributable to genetics (Koeleman,
2018), with many considered to have polygenic inheritance patterns
(Hildebrand et al., 2013; Koeleman, 2018). Furthermore, many
genes mutated in severe early-onset genetic epilepsies have also
been implicated in other types of epilepsy, either as milder
mutations (Qaiser et al., 2020), as genetic modifiers (Mirza et al.,
2017), or on the basis of network analysis showing overlap between
genetic causes and drug targets (Delahaye-Duriez et al., 2016). In
addition, it is becoming clear that diverse neurodevelopmental
disorders converge onto common molecular pathways (Auerbach
et al., 2011; Barnes et al., 2015). It is therefore possible that animal
models of monogenic epilepsies may yield therapies with broader
treatment applications.
If genetic models can lead to the development and testing of
specific therapies aimed at monogenic epilepsies, the same drugs
can then be tested in induced seizure models on the basis that
altering the expression or function of target genes may have wider
applicability. This can, in turn, benefit much broader patient
populations and thus help to alleviate problems associated with
epilepsy and other neurodevelopmental disorders in large numbers
of individuals and their families.
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